Ayahuasca and Depression: What the Research Actually Shows

The honest answer is "promising but preliminary." A handful of small clinical studies, most notably a 2019 randomised controlled trial in treatment-resistant depression, found that a single Ayahuasca session reduced depression scores faster than placebo, with effects lasting about a week. That is a real and interesting signal. It is not proof that Ayahuasca treats depression, it is nowhere near regulatory approval, and it is not a reason to stop or replace any care you are currently receiving.

What the research actually shows

The strongest single piece of evidence is a randomised, placebo-controlled trial published in Psychological Medicine in 2019 by Palhano-Fontes and colleagues in Natal, Brazil.^[1] Twenty-nine people with treatment-resistant depression, meaning they had not improved on at least two prior antidepressants, received either a single dose of Ayahuasca or a carefully designed "active" placebo (a bitter, brownish liquid intended to mimic Ayahuasca's taste and mild gut effects).

The results were genuinely striking for such a difficult patient group. Seven days after a single session, response rates (a 50% or greater drop in depression scores) were 57% in the Ayahuasca group versus 20% on placebo on one standard scale, and 64% versus 27% on another.^[1] The between-group effect sizes were large. An earlier open-label study by the same Brazilian research network reported rapid reductions in depression severity that persisted for around three weeks after one dose.^[2]

So far, the picture is encouraging. But the size and shape of the evidence matter just as much as the headline numbers.

How strong is the evidence, really?

Three caveats should sit alongside every optimistic summary.

The studies are small and few. The landmark RCT enrolled 29 people. A 2024 network meta-analysis in The BMJ comparing psychedelics and escitalopram for depression could only draw on a handful of trials in total, and rated much of the certainty of evidence as moderate-to-low.^[3] For Ayahuasca specifically, the controlled data is thin, a few dozen patients, not the thousands that underpin approved antidepressants.

Blinding is a serious problem. In a depression drug trial you ideally want neither the patient nor the rater to know who got the real drug. With a powerful psychoactive substance, almost everyone can tell. This "functional unblinding" means expectancy, hoping or believing you got the active treatment, can inflate the apparent benefit.^[3] Researchers across psychedelic science treat this as one of the field's central unsolved methodological problems, and it applies squarely to Ayahuasca.

Single dose, short follow-up. The RCT measured outcomes to day 7. We do not yet have good controlled data on whether a single session helps for months, whether repeated sessions are safe and effective, or who relapses and when.

A significant antidepressant effect was observed compared with placebo, but the number of participants was modest, and follow-up was short.

Why retreats are not the same as research

This is the distinction that matters most for a reader weighing a real-world decision. The clinical trials above took place in hospitals, with medical screening, standardised preparations, trained staff, and emergency support. A great deal of Ayahuasca drinking happens in ceremonial and retreat settings that look nothing like that.

Large naturalistic surveys do report that many people feel their mood improves after ceremonial use. The Global Ayahuasca Survey, the biggest such dataset, found most respondents said their depression or anxiety symptoms improved.^[4] But self-selected surveys cannot establish cause and effect: people who had a good experience are likelier to respond, there is no control group, and there is no medical oversight built in. Encouraging perceptions are not the same as clinical proof, and a retreat is not a trial. If you are exploring this route, our guides on what Ayahuasca is and how to choose a retreat safely are a more grounded starting point than any single study.

Is it safe? The risks you should weigh

Antidepressant potential has to be read against a real risk profile. The same Global Ayahuasca Survey found that around 70% of participants reported a physical adverse effect, most commonly vomiting and nausea, which is expected, though only about 2% sought medical attention.^[4] More notably, over half reported some adverse mental health effect in the weeks or months afterward; most framed these as part of a difficult-but-constructive process, but around 12% of that group sought professional support.^[4]

There are also specific, serious risks that depression makes more relevant, not less:

• Drug interactions. Ayahuasca contains MAO inhibitors, which can interact dangerously with several antidepressants (SSRIs, SNRIs and especially other MAOIs). This is covered in detail in our piece on Ayahuasca and antidepressants.
• Cardiovascular and psychiatric risk. Ayahuasca raises heart rate and blood pressure, and there are reports of triggering or worsening serious mental-health episodes in vulnerable people. See who should not take Ayahuasca and the broader safety and contraindications overview.

Is Ayahuasca an approved treatment for depression?

No. As of 2026, no psychedelic, Ayahuasca included, is an approved treatment for depression in the United States, the United Kingdom, or comparable jurisdictions. DMT, the principal psychoactive compound, is a Schedule I substance in the US and a Class A drug in the UK. Regulatory attention has focused mainly on psilocybin and MDMA programmes, and even those have not crossed the approval line for routine depression care.^[5]

That legal reality has practical consequences: outside a sanctioned clinical trial or a specific religious exemption, participation is unregulated and, in many places, illegal, with no quality control over what is in the brew and no guaranteed medical safety net.

What a careful reader should take from this

Ayahuasca is one of several psychedelics under serious scientific investigation for depression, and the early controlled data, especially the 2019 RCT, is interesting enough to justify the larger, better-designed trials now needed.^[1][3] But "interesting early signal" and "proven treatment" are very different things, and the honest summary today is firmly in the first category.

If you are living with depression, the safest, evidence-based path remains working with a qualified clinician on treatments that are tested and supervised. Ayahuasca research is worth following with curiosity. It is not, on the current evidence, a substitute for care.